CompletedPhase 1

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

United States12 participantsStarted 2020-08-27

Plain-language summary

This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males or females, of any race, between 18 and 80 years of age, inclusive, at screening.
✓. Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.
✓. Subjects with normal hepatic function must be in good health.
✓. Subjects must meet the criteria for moderate hepatic impairment based on Child Pugh B.

Exclusion criteria

✕. Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study.
✕. Positive serology test results for hepatitis B surface antigen and/or human immunodeficiency virus 1/2.
✕. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.
✕. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days prior to study drug administration, unless deemed acceptable by the medical monitor and sponsor.
✕. Subject has used prescription drugs within 30 days of study drug administration, with the exception of established therapy for hepatic disease and the treatment of associated disorders that have been stable for at least 30 days before study drug administration, as approved by the investigator and in consultation with the medical monitor.

What they're measuring

Pharmacokinetic Parameter: Maximum observed concentration (Cmax)

Timeframe: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Paramete: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)

Timeframe: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)

Timeframe: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Pharmacokinetic Parameter: Time of the maximum observed concentration (tmax)

Timeframe: 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, and 264 hours postdose.

Safety of KBP-5074 by assessing the number of adverse events, laboratory abnormalities, ECGs, vital signs and physical examinations

Timeframe: Up to 12 days

Trial details

NCT IDNCT04534699

SponsorKBP Biosciences

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-11-19

View on ClinicalTrials.gov More Moderate Hepatic Impairment trials

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males or females, of any race, between 18 and 80 years of age, inclusive, at screening.
✓. Body mass index between 18.0 and 40.0 kg/m2, inclusive, at screening.
✓. Subjects with normal hepatic function must be in good health.
✓. Subjects must meet the criteria for moderate hepatic impairment based on Child Pugh B.

Exclusion criteria

✕. Significant history or clinical manifestation of any medical history, as determined by the investigator not appropriate to participate in this study.
✕. Positive serology test results for hepatitis B surface antigen and/or human immunodeficiency virus 1/2.
✕. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing, whichever is longer.
✕. Use of mineralocorticoids or MRAs (eg, spironolactone or eplenerone) within 90 days prior to study drug administration, unless deemed acceptable by the medical monitor and sponsor.
✕. Subject has used prescription drugs within 30 days of study drug administration, with the exception of established therapy for hepatic disease and the treatment of associated disorders that have been stable for at least 30 days before study drug administration, as approved by the investigator and in consultation with the medical monitor.